Psychiatry Research: Neuroimaging
Volume 194, Issue 3 , Pages 212-218 , 30 December 2011

Dopaminergic mechanisms of target detection — P300 event related potential and striatal dopamine

  • Oliver Pogarell

      Affiliations

    • Department of Psychiatry, Ludwig-Maximilian-University of Munich, Munich, Germany
    • Corresponding Author InformationCorresponding author at: Department of Psychiatry, Ludwig-Maximilian-University of Munich, Nüssbaumerstr. 7, D-80336 Munich, Germany. Tel.: +49 0 89 5160 5540; fax: +49 0 89 5160 5542.
    • ,
  • Frank Padberg

      Affiliations

    • Department of Psychiatry, Ludwig-Maximilian-University of Munich, Munich, Germany
    • ,
  • Susanne Karch

      Affiliations

    • Department of Psychiatry, Ludwig-Maximilian-University of Munich, Munich, Germany
    • ,
  • Felix Segmiller

      Affiliations

    • Department of Psychiatry, Ludwig-Maximilian-University of Munich, Munich, Germany
    • ,
  • Georg Juckel

      Affiliations

    • Department of Psychiatry, University of Bochum, Bochum, Germany
    • ,
  • Christoph Mulert

      Affiliations

    • Department of Psychiatry, University of Hamburg, Hamburg, Germany
    • ,
  • Ulrich Hegerl

      Affiliations

    • Department of Psychiatry, University of Leipzig, Germany
    • ,
  • Klaus Tatsch

      Affiliations

    • Department of Nuclear Medicine, Ludwig-Maximilian-University of Munich, Munich, Germany
    • Department of Nuclear Medicine, Municipal Hospital of Karlsruhe Inc., Karlsruhe, Germany
    • ,
  • Walter Koch

      Affiliations

    • Department of Nuclear Medicine, Ludwig-Maximilian-University of Munich, Munich, Germany

Received 29 October 2010 ,Revised 30 December 2010 ,Accepted 6 February 2011.

References 

  1. Abi-Dargham A, Laruelle M, Seibyl J, Rattner Z, Baldwin RM, Zoghbi SS, et al. SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil: kinetic and equilibrium paradigms. Journal of Nuclear Medicine. 1994;35:228–238
  2. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. The American Journal of Psychiatry. 1998;155:761–767
  3. Berman SM, Noble EP, Antolin T, Sheen C, Conner BT, Ritchie T. P300 development during adolescence: effects of DRD2 genotype. Clinical Neurophysiology. 2006;117:649–659
  4. Carson RE, Channing MA, Blasberg RG, Dunn BB, Cohen RM, Rice KC, et al. Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. Journal of Cerebral Blood Flow and Metabolism. 1993;13:24–42
  5. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Transactions on Nuclear Science. 1978;25:638–642
  6. Cropley VL, Fujita M, Innis RB, Nathan PJ. Molecular imaging of the dopaminergic system and its association with human cognitive function. Biological Psychiatry. 2006;59:898–907
  7. Dierks T, Maurer K. P300 evoked by an auditory and a visual paradigm and a semantic task. Psychiatry Research. 1989;29:439–441
  8. Donchin E, Coles M. Is the P300 component a manifestation of context updating?. The Behavioral and Brain Sciences. 1988;11:357–374
  9. Duncan GE, Sheitman BB, Lieberman JA. An integrated view of pathophysiological models of schizophrenia. Brain Research Reviews. 1999;29:250–264
  10. Ebert D, Feistel H, Loew T, Pirner A. Dopamine and depression–striatal dopamine D2 receptor SPECT before and after antidepressant therapy. Psychopharmacology (Berlin). 1996;126:91–94
  11. Ford JM, Pfefferbaum A, Roth W. P3 and schizophrenia. Annals of the New York Academy of Sciences. 1992;658:146–162
  12. Frodl T, Hampel H, Juckel G, Burger K, Padberg F, Engel RR, et al. Value of event-related P300 subcomponents in the clinical diagnosis of mild cognitive impairment and Alzheimer's Disease. Psychophysiology. 2002;39:175–181
  13. Frodl T, Meisenzahl EM, Muller D, Holder J, Juckel G, Moller HJ, et al. P300 subcomponents and clinical symptoms in schizophrenia. International Journal of Psychophysiology. 2002;43:237–246
  14. Frodl-Bauch T, Bottlender R, Hegerl U. Neurochemical substrates and neuroanatomical generators of the event-related P300. Neuropsychobiology. 1999;40:86–94
  15. Gallinat J, Riedel M, Juckel G, Sokullu S, Frodl T, Moukhtieva R, et al. P300 and symptom improvement in schizophrenia. Psychopharmacology (Berlin). 2001;158:55–65
  16. Gallinat J, Mulert C, Bajbouj M, Herrmann WM, Schunter J, Senkowski D, et al. Frontal and temporal dysfunction of auditory stimulus processing in schizophrenia. Neuroimage. 2002;17:110–127
  17. Gangadhar BN, Ancy J, Janakiramaiah N, Umapathy C. P300 amplitude in non-bipolar, melancholic depression. Journal of Affective Disorders. 1993;28:57–60
  18. Halgren E, Baudena P, Clarke JM, Heit G, Liegeois C, Chauvel P, et al. Intracerebral potentials to rare target and distractor auditory and visual stimuli. I. Superior temporal plane and parietal lobe. Electroencephalography and Clinical Neurophysiology. 1995;94:191–220
  19. Halgren E, Baudena P, Clarke JM, Heit G, Marinkovic K, Devaux B, et al. Intracerebral potentials to rare target and distractor auditory and visual stimuli. II. Medial, lateral and posterior temporal lobe. Electroencephalography and Clinical Neurophysiology. 1995;94:229–250
  20. Halgren E, Marinkovic K, Chauvel P. Generators of the late cognitive potentials in auditory and visual oddball tasks. Electroencephalography and Clinical Neurophysiology. 1998;106:156–164
  21. Hegerl U. Event-related potentials in psychiatry: a new perspective. Pharmacopsychiatry. 1994;27:47–48
  22. Hegerl U, Frodl-Bauch T. Dipole source analysis of P300 component of the auditory evoked potential: a methodological advance?. Psychiatry Research. 1997;74:109–118
  23. Hegerl U, Juckel G, Muller-Schubert A, Pietzcker A, Gaebel W. Schizophrenics with small P300: a subgroup with a neurodevelopmental disturbance and a high risk for tardive dyskinesia?. Acta Psychiatrica Scandinavica. 1995;91:120–125
  24. Johnson R. A triarchic model of P300 amplitude. Psychophysiology. 1986;23:367–384
  25. Juckel G, Muller-Schubert A, Gaebel W, Hegerl U. Residual symptoms and P300 in schizophrenic outpatients. Psychiatry Research. 1996;65:23–32
  26. Kahkonen S, Ahveninen J, Jaaskelainen IP, Kaakkola S, Naatanen R, Huttunen J, et al. Effects of haloperidol on selective attention: a combined whole-head MEG and high-resolution EEG study. Neuropsychopharmacology. 2001;25:498–504
  27. Kawasaki T, Tanaka S, Wang J, Hokama H, Hiramatsu K. Abnormalities of P300 cortical current density in unmedicated depressed patients revealed by LORETA analysis of event-related potentials. Psychiatry and Clinical Neurosciences. 2004;58:68–75
  28. Kayser J, Bruder GE, Tenke CE, Stewart JE, Quitkin FM. Event-related potentials (ERPs) to hemifield presentations of emotional stimuli: differences between depressed patients and healthy adults in P3 amplitude and asymmetry. International Journal of Psychophysiology. 2000;36:211–236
  29. Kemp AH, Hopkinson PJ, Hermens DF, Rowe DL, Sumich AL, Clark CR, et al. Fronto-temporal alterations within the first 200ms during an attentional task distinguish major depression, non-clinical participants with depressed mood and healthy controls: a potential biomarker?. Human Brain Mapping. 2009;30:602–614
  30. Kemp AH, Pe Benito L, Quintana DS, Clark CR, McFarlane A, Mayur P, et al. Impact of depression heterogeneity on attention: an auditory oddball event related potential study. Journal of Affective Disorders. 2010;123:202–207
  31. Kiehl KA, Laurens KR, Duty TL, Forster BB, Liddle PF. Neural sources involved in auditory target detection and novelty processing: an event-related fMRI study. Psychophysiology. 2001;38:133–142
  32. Koch W, Radau PE, Hamann C, Tatsch K. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. Journal of Nuclear Medicine. 2005;46:1109–1118
  33. Kung HF, Alavi A, Chang W, Kung MP, Keyes JW, Velchik MG, et al. In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans. Journal of Nuclear Medicine. 1990;31:573–579
  34. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. Journal of Cerebral Blood Flow and Metabolism. 2000;20:423–451
  35. Laruelle M, Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. Journal of Psychopharmacology. 1999;13:358–371
  36. Laruelle M, Abi-Dargham A, al-Tikriti MS, Baldwin RM, Zea-Ponce Y, Zoghbi SS, et al. SPECT quantification of [123I]iomazenil binding to benzodiazepine receptors in nonhuman primates: II. Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters. Journal of Cerebral Blood Flow & Metabolism. 1994;14:453–465
  37. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, et al. SPECT imaging of striatal dopamine release after amphetamine challenge. Journal of Nuclear Medicine. 1995;36:1182–1190
  38. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences of the United States of America. 1996;93:9235–9240
  39. Luthringer R, Rinaudo G, Toussaint M, Bailey P, Muller G, Muzet A, et al. Electroencephalographic characterization of brain dopaminergic stimulation by apomorphine in healthy volunteers. Neuropsychobiology. 1999;39:49–56
  40. Malhi GS, Berk M. Does dopamine dysfunction drive depression?. Acta Psychiatrica Scandinavica.Supplementum. 2007;116–124
  41. Malhi GS, Parker GB, Greenwood J. Structural and functional models of depression: from sub-types to substrates. Acta Psychiatrica Scandinavica. 2005;111:94–105
  42. McCarthy G, Wood CC. Intracranial recordings of endogenous ERPs in humans. Electroencephalography and Clinical Neurophysiology. Supplement. 1987;39:331–337
  43. McKetin R, Ward PB, Catts SV, Mattick RP, Bell JR. Changes in auditory selective attention and event-related potentials following oral administration of d-amphetamine in humans. Neuropsychopharmacology. 1999;21:380–390
  44. Meyer JH, McNeely HE, Sagrati S, Boovariwala A, Martin K, Verhoeff NP, et al. Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. The American Journal of Psychiatry. 2006;163:1594–1602
  45. Mulert C, Jager L, Schmitt R, Bussfeld P, Pogarell O, Moller HJ, et al. Integration of fMRI and simultaneous EEG: towards a comprehensive understanding of localization and time-course of brain activity in target detection. Neuroimage. 2004;22:83–94
  46. Mulert C, Pogarell O, Juckel G, Rujescu D, Giegling I, Rupp D, et al. The neural basis of the P300 potential. Focus on the time-course of the underlying cortical generators. European Archives of Psychiatry and Clinical Neurosciences. 2004;254:190–198
  47. Mulert C, Juckel G, Giegling I, Pogarell O, Leicht G, Karch S, et al. A Ser9Gly polymorphism in the dopamine D3 receptor gene (DRD3) and event-related P300 potentials. Neuropsychopharmacology. 2006;31:1335–1344
  48. Neuhaus AH, Luborzewski A, Rentzsch J, Brakemeier EL, Opgen-Rhein C, Gallinat J, et al. P300 is enhanced in responders to vagus nerve stimulation for treatment of major depressive disorder. Journal of Affective Disorders. 2007;100:123–128
  49. Nishimura N, Ogura C, Ohta I. Effects of the dopamine-related drug bromocriptine on event-related potentials and its relation to the law of initial value. Psychiatry and Clinical Neurosciences. 1995;49:79–86
  50. Noble EP, Berman SM, Ozkaragoz TZ, Ritchie T. Prolonged P300 latency in children with the D2 dopamine receptor A1 allele. American Journal of Human Genetics. 1994;54:658–668
  51. Oranje B, Gispen-de Wied CC, Westenberg HG, Kemner C, Verbaten MN, Kahn RS. No effects of l-dopa and bromocriptine on psychophysiological parameters of human selective attention. Journal of Psychopharmacology. 2006;20:789–798
  52. Oranje B, Gispen-de Wied CC, Westenberg HG, Kemner C, Verbaten MN, Kahn RS. Haloperidol counteracts the ketamine-induced disruption of processing negativity, but not that of the P300 amplitude. The International Journal of Neuropsychopharmacology. 2009;12:823–832
  53. Pfefferbaum A, Wenegrat BG, Ford JM, Roth WT, Kopell BS. Clinical application of the P3 component of event-related potentials. II. Dementia, depression and schizophrenia. Electroencephalography and Clinical Neurophysiology. 1984;59:104–124
  54. Pfefferbaum A, Ford JM, White PM, Mathalon D. Event-related potentials in alcoholic men: P3 amplitude reflects family history but not alcohol consumption. Alcoholism, Clinical and Experimental Research. 1991;15:839–850
  55. Pogarell O, Koch W, Popperl G, Tatsch K, Jakob F, Zwanzger P, et al. Striatal dopamine release after prefrontal repetitive transcranial magnetic stimulation in major depression: preliminary results of a dynamic [123I] IBZM SPECT study. Journal of Psychiatric Research. 2006;40:307–314
  56. Polich J. P300 and Alzheimer's disease. Biomedicine & Pharmacotherapy. 1989;43:493–499
  57. Polich J, Pollock VE, Bloom FE. Meta-analysis of P300 amplitude from males at risk for alcoholism. Psychological Bulletin. 1994;115:55–73
  58. Santosh PJ, Malhotra S, Raghunathan M, Mehra YN. A study of P300 in melancholic depression–correlation with psychotic features. Biological Psychiatry. 1994;35:474–479
  59. Schmitt GJ, Frodl T, Dresel S, la Fougere C, Bottlender R, Koutsouleris N, et al. Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients. European Archives of Psychiatry and Clinical Neurosciences. 2006;256:115–121
  60. Shelley AM, Catts SV, Ward PB, Andrews S, Mitchell P, Michie P, et al. The effect of decreased catecholamine transmission on ERP indices of selective attention. Neuropsychopharmacology. 1997;16:202–210
  61. Sohn YH, Kim GW, Huh K, Kim JS. Dopaminergic influences on the P300 abnormality in Parkinson's disease. Journal of the Neurological Sciences. 1998;158:83–87
  62. Stanzione P, Fattapposta F, Giunti P, D'Alessio C, Tagliati M, Affricano C, et al. P300 variations in Parkinsonian patients before and during dopaminergic monotherapy: a suggested dopamine component in P300. Electroencephalography and Clinical Neurophysiology. 1991;80:446–453
  63. Sutton S, Braren M, Zubin J, John ER. Evoked-potential correlates of stimulus uncertainty. Science. 1965;150:1187–1188
  64. Takeshita S, Ogura C. Effect of the dopamine D2 antagonist sulpiride on event-related potentials and its relation to the law of initial value. International Journal of Psychophysiology. 1994;16:99–106
  65. Urretavizcaya M, Moreno I, Benlloch L, Cardoner N, Serrallonga J, Menchon JM, et al. Auditory event-related potentials in 50 melancholic patients: increased N100, N200 and P300 latencies and diminished P300 amplitude. Journal of Affective Disorders. 2003;74:293–297
  66. Verleger R. Sequential effects on P3 in a counting task: a partial replication. Biological Psychology. 1987;25:221–246
  67. Verleger R. Event related potentials and cognition: a critique of the context updating hypothesis and an alternative interpretation of P3. The Behavioral and Brain Sciences. 1988;11:343–356

PII: S0925-4927(11)00068-0

doi: 10.1016/j.pscychresns.2011.02.002

Psychiatry Research: Neuroimaging
Volume 194, Issue 3 , Pages 212-218 , 30 December 2011

Article Tools

* Image Usage & Resolution